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Abstract. The aim of this study was to investigate the presence of microaggregates of macrophages (CD-
68 positive cells) in macroscopically normal buccal mucosa in patients with inflammatory bowel disease 
(IBD). Fifty two patients with clinically and pathohistologically diagnosed IBD, thirty patients with 
Crohn’s disease (CD), twenty two patients with ulcerative colitis (UC), and twenty five controls, matched 
for sex and age, were involved. The occurrence of CD-68 positive cells microaggregates was more fre-
quent in CD patients comparing with UC patients (P = 0.0093), and the controls (P = 0.0001) respective-
ly. There was no statistically significant difference in occurrence of CD-68 positive microaggregates in 
patients with positive microbiological findings (P = 0.8258). The results suggest that microaggregates of 
macrophages are more frequently present in apparently normal buccal mucosa in patients with CD than in 
patients with UC independently of microbiological findings. Therefore, it could be a potential marker for 
differentiating patients with Crohn’s disease from UC patients, when standard tools failed. (doi: 
10.5562/cca1779) 
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INTRODUCTION 
Inflammatory bowel disease (IBD) is a chronic in-
flammatory condition of the gastrointestinal tract that 
manifests as ulcerative colitis (UC) or Crohn's disease 
(CD). The studies indicate that UC and CD are hetero-
geneous diseases characterized by various genetic 
abnormalities that lead to aggressive T-cell responses 
towards a subset of commensally enteric bacteria.1 
Furthermore, there is a need to classify patients in 
relation to phenotypic characteristics of the disease.2 
So, distinguishing the two conditions (CD and UC) is 
important because of the similar, but different thera-
peutic implications (medical and surgical treatment). 
Differential diagnosis is based upon clinical, radiolog-
ical, endoscopic and histological criteria but in about 
10 % of patients it may be difficult to differentiate 
Crohn's colitis from UC.3,4 Colitis yet to be classified 
is the new term for the cases where a definitive distinc-
tion between UC, CD, or other cause of colitis cannot 
be established after the history, endoscopy, 
patohistology and radiology have been taken into ac-
count.5 Serological markers and the new fecal markers 
can differentiate active IBD from inactive IBD as well 
as from irritable bowel syndrome (IBS).6,7 Genetics 
also plays a role, but until now, we have no strict dis-
criminating markers for CD and UC as well. So, genet-
ic testing is currently not recommended for routine 
practice.4 Recently, “tissue factor predictors” or muco-
sal biomarkers are considered as potential predictor in 
disease progression or response to the therapy.8 
Microaggregates of immunostained macrophages in 
noninflammed gastrointestinal mucosa seem to be a 
useful method for differentiating Crohn's colitis from 
UC.3,5 The aim of this study was to investigate the 
presence of microaggregates of CD-68 positive cells 
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(macrophages) in macroscopically normal buccal mu-
cosa in patients with IBD in order to determinate pos-




A cross-sectional study involved 52 patients, with a 
previously clinical and pathohistological diagnosed 
IBD, 30 with Crohn’s disease (CD) and 22 with ul-
cerative colitis (UC). The patients were in- and outpa-
tients of the Department of Gastroenterology at the 
Clinical Hospital Centre Rijeka. The control group was 
constituted of 25 patients who were hospitalized for 
trauma in maxillofacial region at the Department of 
Maxillofacial Surgery at the Clinical Hospital Centre 
Rijeka, and needed surgical treatment in oral cavity. 
The two groups were matched for sex and age (Table 
1). All the subjects were informed about purpose of 
this study and they freely agreed to be part of it. They 
all signed an informed consent that was approved by 
the Hospital Ethics Committee. All of them completed 
a questionnaire that included medical history and med-
ications used. The diagnosis of CD and UC were es-
tablished owing to ECCO consensus for UC and CD 
diagnosis as well.4,5 The patients with CD were divid-
ed into active and inactive group based on CDAI 
(Crohn's Disease Activity Index) classification consid-
ering the CDAI<150 as the remission. Patients with 
UC were classified according to the Montreal classifi-
cation of severity of the disease.9,10 IBD was excluded 
in control group by history, laboratory values and 
physical exam. 
The gingival and dental health status of patients 
with IBD and the control group has been investigated. 
 
Histopathology and Immunohistochemistry 
In local anesthesia with 2 mL of 2 % xylocain, appar-
ently normal (healthy) buccal mucosa in the area of 
palatal’s arches was biopsied. The wound was sewed 
up with resorptive material. Biopsy specimen’s sizes 
of 0.5−1.0 cm were fixed in 10 % formalin overnight 
and embedded in paraffin (50−56 °C). Two serial sec-
tions (3−4 μm) were cut and deparaffinised in xylene 
and rehydrated through graded alcohol (5 minutes in 
each). One of them was stained with hematoxylin and 
eosin (HE) for histopathological screening and the 
other was prepared for immunohistochemistry. 
The sections for immunohistochemistry were 
washed in distilled water and immersed in ethanol with 
3 % hydrogen peroxide to eliminate endogenous pe-
roxidase activity. For antigen retrieval, the slides were 
immersed in preheated TRIS-EDTA buffer (pH 9) on 
96−99 °C. After 10 minutes, the slides were cooled for 
new 20 minutes on room temperature and treated with 
normal mouse serum for 20 minutes to block nonspe-
cific binding. In Dako Techmate Horizon automated 
immunostainer sections were incubated with monoclo-
nal mouse anti-human CD68 antibody (clone-KP1; 
M0814) at a dilution of 1:2000. For negative control 
DakoCytomation Mouse IgG1, code no. X 0931, dilut-
ed to the same concentration as the primary antibody 
was used. Dako Real Detection System, Peroxi-
dase/DAB+, Rabbit/Mouse, was used in immunohisto-
chemistry together with Dako automated 
immunostaining instruments (code K5001) yelling 
brown precipitate. For contrast staining hematoxylin 
was used. After dehydration in 70, 96 and 100 % alco-
hol, in each for 3 minutes; twice in xylene substitute, 
slides were dried and mounted with Entelan. Images 
from an Olympus (BX40) scope were captured and 
edited with an Olympus digital camera. 
 
Histological Criteria for the Microaggregates of Mac-
rophages 
The presence of microaggregates of macrophages at the 
sections from buccal mucosa was investigated. As ag-
gregate were considered cluster of 5−10 CD-68 positive 
cells in close contact with each other. The patient was 
claimed as being positive when at least one 
microaggregate was found. 
 
Microbiology 
Unstimulated whole saliva samples, and oral mucosa 
swabs (Copan Venturi Transystem; Copan, Brescia, 
Italy) were collected in sterile condition and cultured 
by standard methods. Serial ten-fold dilutions of the 
saliva samples in sterile phosphate-buffered saline 
(PBS, pH 7.4) were plated onto different media. The 
Table 1. Demographic parameters of involved subjects 
 IBD 
(n = 52) 
Crohn's Disease 
(n = 30) 
Ulcerative Colitis 
(n = 22) 
Control 
(n = 25) 
Age (years) 
Mean ± s.d. 40.09 ± 16.32 36.10 ± 16.51 45.54  ± 14.72 35.36 ± 17.76 
Range 18–79 18–79 23–74 18–72 
Females : Males         28 : 24 16 : 14 12 : 10 10 : 15 
Remission : Activity 21 : 31 11 : 19 10 : 12  
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colony-forming units (CFU) of microorganisms on 
each plate were counted after incubation at 37 °C / 48 
h in ambient air for yeasts, and 37 °C / 24 h in 5 % 
CO2 atmosphere for bacteria. Chromalbicans Agar 
(Biolife, Milano, Italy) was used as a selective medi-
um for the isolation and presumptive identification of 
yeasts. Yeast-like colonies growing on primary isola-
tion medium were tested for germ tube (GT) produc-
tion and were identified with the API ID 32C 
(bioMérieux, Marcy l′Etoile, France). GT test was 
performed according to standard methods.11 The API 
ID 32C was used according to the manufacturer's 
instructions. For bacterial cultivation the following 
media were used: blood agar, MacConkey agar and 
DifcoTMCetrimide agar (Becton, Dickinson and 
Company, Franklin Lakes, NJ, USA). A slide aggluti-
nation test was used for identification of Staphylococ-
cus aureus (Slidex Staph-Kit; bioMérieux, Marcy 
l′Etoile, France). Lancefield serogrouping of beta-
hemolytic streptococci was performed using Slidex 
StreptoPlus (bioMérieux, Marcy l′Etoile, France). 
Enterobacteriaceae were identified by the API 20 E 
test (bioMérieux, Marcy l′Etoile, France). 
API 20 NE system (bioMérieux, Marcy l′Etoile, 




Statistical analyses were performed as a cross-sectional 
analysis between patients with UC vs. CD vs. controls. 
Data are expressed as means ± SD. Descriptive statistic 
were done with all data. Fisher’s exact, two-tailed test 
was applied; given the small number of samples within 
each group. The level of P < 0.05 was defined as statis-
tically significant. STATISTICA version 8.0 was used 
for all calculations. 
 
RESULTS 
Fifty-two IBD patients and 25 controls were studied. Sex, 
age, and disease duration and activity distribution are 
presented in Table 1. Pathohistological findings of CD-68 
positive cells microaggregates (immunostained macro-
phages) in buccal mucosa are shown in Figure 1. 
Microaggregates were found in 17 (57 %) patients with 
CD and in 4 (18 %) patients with UC. There were three 
positive control patients for the respective findings. The 
occurrence of CD-68 positive cells was more frequent in 
CD patients comparing with UC patients (P = 0.0093), 
and the controls (P = 0.0001) respectively. There was no 
difference (P = 0.7423) between UC patients and the 
control group regarding the occurrence of the same 
microaggregates (Figure 2). The sensitivity of CD-68 
microaggregate finding in buccal mucosa for CD diagno-
sis was 57 %, with high specificity of 82 %. There were 
no statistical significance in appearances of this findings 
between male and female with IBD (P = 0.1621), neither 
with CD (P = 0.7131) nor with UC (P = 0.0963). Fur-
thermore, comparing macrophage microaggregate in 
buccal mucosa in the patients with active CD and patients 
in remission, no statistical significance was detected (P = 
0.5567) (Figure 3). The occurrence of CD-68 
microaggregate was not more frequent in CD patients 
with upper gastrointestinal involvement (P = 0.348). 
Also, it didn’t depend on the duration of the disease (P = 
0.8193). Furthermore, there was no statistical significance 
in appearance of Candida albicans in saliva or in smear 
of oral cavity neither between patients with IBD and 
control group (P = 0.8165), nor between CD and UC 
patients (P = 0.6637). Also, there was no statistically 
significant difference in occurrence of CD-68 positive 
microaggregates in patients with positive microbiological 
findings (P = 0.8258). The presence of aphthous lesion  
 
 
Figure 1. Macrophages in buccal mucosa: Immunohistology of formalin fixed, paraffin embedded buccal mucosa, incubated with
monoclonal CD68 antibody. Cluster of CD-68 positive cells (brown staining). Contrastained with hematoxilin. Magnification
200 × (A), 400 × (B). 
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was not connected with more frequent occurrence of CD-
68 positive microaggregate (P = 0.5579). 
 
DISCUSSION 
Nowadays, distinguishing not only CD from UC, but 
also different phenotypes of CD and UC represents an 
imperative of clinical approach to inflammatory bowel 
disease treatment, and it would be ideal to have validat-
ed prognostic markers as a tool for predicting future 
behaviour of disease. So, recognition of importance in 
finding typical entities has induced the large searching 
among clinicians as well as laboratory workers.8,12−14 In 
our previous study we investigate clinical relevance of 
the serum enzyme dipeptidyl peptidase IV (DPP IV) 
activity in patients with inflammatory bowel disease and 
showed that it couldn’t be the discriminating marker 
among CD and UC.15 In accordance with the results of 
the present study, microaggregates of CD-68 positive 
cells in macroscopic healthy buccal mucosa could be 
helpful marker that can make difference between 
Crohn's disease and ulcerative colitis patients. Crohn’s 
disease can affect any part of the gut, and lesions can be 
found in the oral cavity as disease manifestation or as 
disease related lesions.16 Oral lesions have been de-
 
Figure 2. CD68-positive cells in sections of buccal mucosa: Comparisons between patients with Crohn's disease (CD; n = 17/30),
ulcerative colitis (UC; n = 4/22), Inflammatory bowel disease (IBD; n = 21/52) and control individuals (CTRL; n = 3/25). 
 
Figure 3. CD68-positive cells in sections of buccal mucosa in patients with Crohn' disease: Microaggregates were found in 17
patients with CD (n = 30). Among patients there were nine with active disease and eight in remission. No statistical significance
was detected comparing macrophage microaggregate in buccal mucosa in the patients with active CD and patients in remission
(P = 0.5567). 
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scribed more frequent in Crohn’s disease than in ulcera-
tive colitis. The lesions may precede or accompany 
gastrointestinal disease and can be the only site of in-
volvement. In Crohn’s disease there are aphtoid ulcera-
tions, granulomatous autoimmune-like changes in minor 
salivary glands, pyostomatitis vegetans, dental erosion, 
candidiasis and a high prevalence of caries. In ulcerative 
colitis patients oral lesions may include mucosal ulcers, 
pyostomatitis vegentans, diffuse pustules and lichen 
planus.16−20 Patients with active Crohn’s disease have 
more oral signs compared with non-active Crohn’s 
disease.17 All those findings were specified in macro-
scopic changed mucosa, but microaaggregates of CD-68 
positive cells, in healthy oral mucosa of IBD patients 
have not yet been described. 
Furthermore, human oral cavity contains more 
than 500 bacterial species inhabiting the teeth, gingival 
crevices, buccal mucosa and tongue.21 Clusters of CD-
68 positive cells were found in some infective diseases; 
in Borrelia burgdorferi and Eikenella corrodens infec-
tions, but also in intestinal Behcet’s disease or some 
inflammatory tumor associated with infection.22−25 In 
present study sporadic findings of enterobacteriaceae, 
streptococci and staphylococci were not statistically 
different in patients with IBD comparing to the controls. 
Also, there was no statistical significance in appearance 
of Candida albicans in saliva or in smear of oral cavity 
neither between patients with IBD and control group, 
nor between CD and UC patients. There was no statisti-
cally significant difference in occurrence of CD-68 
positive microaggregates in patients with positive mi-
crobiological findings, so it could be excluded as the 
possible reason of microaggregates. Yao and co-
workers detected microaggregates of immunostained 
macrophages in a biopsy specimen taken from non-
inflamed gastroduodenal mucosa only in patients with 
Crohn’s colitis, but not in ulcerative colitis.3 So, it was 
described as a useful histological marker in differentiat-
ing Crohn’s colitis from ulcerative colitis. As the results 
of the present study in oral mucosa show high specifici-
ty of macrophages microaggegates for Crohn’s disease 
it could also be a very simple tool in differentiating 
ulcerative colitis from Crohn’s colitis. Additionally, the 
appearances of microaggregates of macrophages in 
buccal mucosa were not in a correlation neither with 
upper gastrointestinal involvement, nor disease activity 
and it could be used at any time of the disease course. 
So it could be helpful in selecting the appropriate medi-
cal and surgical treatment for the individual patients. 
Ileal pouch-anal anastomosis (IPAA) is the most recent-
ly devised procedure for ulcerative colitis and avoids the 
need for permanent ileostomy. On the contrary, evi-
dence suggests that in patients with Crohn’s disease 
complication and failure rates are higher after IPAA. At 
present, an IPAA is not recommended in a patient with 
Crohn’s disease.26,27 
In conclusion, microaggregates of CD-68 positive 
cells in macroscopic healthy buccal mucosa could be 
helpful marker which can contribute to differentiation 
between Crohn's colitis and UC patients. Further studies 
regarding microaggreagates of CD-68 positive cells, as 
a potential disease predictor, are necessary. 
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